GENB · Insider trading · 13F holders · Congress trades
Generate Biomedicines, Inc. (GENB)
Who is buying and selling GENB: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 8
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $16K
- Congress trades, 12 months
- 0
GENB at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 1 GENB insider filed 1 sale worth $16K on SEC Form 4, and no open-market purchases; 1 of the sales were pre-planned under Rule 10b5-1.
- 8 13F filers hold GENB among their 50 largest positions, worth $1.2B combined. The biggest bets by portfolio weight are ARCH Venture Management, LLC (3.0%), Davern Capital Partners, LP (2.4%) and Braidwell LP (2.1%). In their latest 13Fs, 1 manager opened a new position and 1 added to one.
- No member of Congress has disclosed a trade in GENB.
- GENB last closed at $15.77 on Oct 29, 2026.
GENB insider trading
Between Aug 1, 2026 and Oct 29, 2026, 1 GENB insider filed 1 sale worth $16K on SEC Form 4, and no open-market purchases; 1 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Arnold Frances | Director | Sale10b5-1 | 1,000 | $16.00 | $16K | SEC |
Who owns GENB? Hedge funds and superinvestors
8 13F filers hold GENB among their 50 largest positions, worth $1.2B combined. The biggest bets by portfolio weight are ARCH Venture Management, LLC (3.0%), Davern Capital Partners, LP (2.4%) and Braidwell LP (2.1%). In their latest 13Fs, 1 manager opened a new position and 1 added to one.
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Flagship Pioneering, LLCHedge fund | 68.7% | $1.1B | 62,673,117 | +0.0% shares | Q2 2026 |
| Braidwell LPHedge fund | 2.1% | $55.4M | 3,283,844 | -8.6% shares | Q2 2026 |
| ARCH Venture Management, LLCVenture capital | 3.0% | $32.8M | 1,944,426 | +0.0% shares | Q2 2026 |
| HarbourVest Partners LLCHedge fund | 17.1% | $29.1M | 1,722,210 | +0.0% shares | Q2 2026 |
| Harvard Management Co IncInvestment manager | 0.4% | $18.7M | 1,111,100 | +0.0% shares | Q2 2026 |
| Nvidia CorpCorporation | 0.0% | $14.1M | 833,325 | +0.0% shares | Q2 2026 |
| Davern Capital Partners, LPInstitutional asset manager | 2.4% | $13.9M | 824,679 | +39.4% shares | Q2 2026 |
| PICTET BANK & TRUST LtdBank & trust | 0.3% | $250K | 16,666 | New | Q3 2026 |
Each manager counts with its latest 13F (Q3 2026: 1, Q2 2026: 7). Screen GENB in the grand portfolio →
GENB stock trades by members of Congress
No member of Congress has disclosed a trade in GENB.
GENB questions and answers
Are insiders buying GENB stock?
Between Aug 1, 2026 and Oct 29, 2026, 1 GENB insider filed 1 sale worth $16K on SEC Form 4, and no open-market purchases; 1 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own GENB?
8 13F filers hold GENB among their 50 largest positions, worth $1.2B combined. The biggest bets by portfolio weight are ARCH Venture Management, LLC (3.0%), Davern Capital Partners, LP (2.4%) and Braidwell LP (2.1%). In their latest 13Fs, 1 manager opened a new position and 1 added to one.
Has Congress traded GENB?
No member of Congress has disclosed a trade in GENB.
Who is the largest holder of GENB?
Among 13F filers, Flagship Pioneering, LLC reports the largest GENB position, $1.1B (62,673,117 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is ARCH Venture Management, LLC's: 3.0% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.